In this study, we designed a new type of chimeric receptor T cell targeting CA125, based on the natural binding of mesothelin to CA125 in patients with ovarian cancer, to reverse the role of this ligand-receptor binding activity in promoting tumor transformation. Here, MUC16 is linked to neoplasm.